Innate Pharma announces transformative strategy to accelerate growth
Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference
Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024 from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma
Innate Pharma highlights abstracts selected for the ASH annual meeting 2024
Innate Pharma releases its 2025 financial calendar
Innate Pharma announces publication in Science Immunology highlighting innovative next-generation ANKET® IPH6501
Innate Pharma reports Third Quarter 2024 Business Update and Financial Results
Innate Pharma highlights data from its innovative oncology portfolio selected for the SITC Annual Meeting 2024
Innate Pharma announces conference call and webcast for third quarter 2024 results and business updates
